title: Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels.
abstract: In vivo antitumoral activity, pharmacokinetics (PK) and biodistribution of a new liposomal formulation of vincristine (VCR-Lip) were compared to VCR in aqueous solution (VCR-Conv). VCR was entrapped into a vesicular phospholipid gel (VPG) consisting of densely packed liposomes. Redispersed VCR-containing VPG (VCR-Lip) consisted of 54% liposomally entrapped and 46% free VCR. In vivo efficacy of VCR-Lip versus VCR-Conv was tested using the s.c. growing human small cell lung carcinoma LXFS 650 and the human mammary carcinoma MX1. PK and biodistribution were evaluated using radiolabeled drug and lipid in LXFS 650 tumor-bearing mice. VCR-Lip at a dose of 1.0 mg/kg (dose near the maximum tolerated dose) led to partial remissions in the MX1 tumor xenograft model (T/C=3.9%). VCR-Conv at an equitoxic dose of 0.6 mg/kg produced only a tumor growth inhibition (T/C=7.0%). In LXFS 650 tumor-bearing mice, VCR-Lip was highly active at doses of 0.75 (T/C=0.7%) and 1.0 (T/C=0.0%) mg/kg, and complete tumor regressions were observed. In contrast, equitoxic doses of VCR-Conv (0.6 mg/kg) resulted only in less pronounced tumor remissions (T/C=4.1%). The PK study revealed that VCR-Lip achieved an over 10-fold higher plasma AUC (22.6 microg x h/ml) than VCR-Conv (2.16 microg x h/ml). Moreover, tumor drug levels were 2.3-fold higher when VCR was injected as VCR-Lip in comparison to VCR-Conv. In some cases, however, VCR-Lip as well as blank VPG appeared to be toxic. We conclude that VCR-Lip is an effective VCR delivery system with superior antitumor activity compared to VCR-Conv. The enhanced efficacy can be explained by sustained release and passive tumor targeting.
authors.affiliation: Tumor Biology Center, Department of Clinical Research, 79106 Freiburg, Germany.
authors.forename: Frank
authors.initials: F
authors.lastname: Güthlein
authors.forename: Angelika M
authors.initials: AM
authors.lastname: Burger
authors.forename: Martin
authors.initials: M
authors.lastname: Brandl
authors.forename: Heinz-Herbert
authors.initials: HH
authors.lastname: Fiebig
authors.forename: Rolf
authors.initials: R
authors.lastname: Schubert
authors.forename: Clemens
authors.initials: C
authors.lastname: Unger
authors.forename: Ulrich
authors.initials: U
authors.lastname: Massing
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010743:Phospholipids / Q000008:administration & dosage*; D012995:Solubility; D014018:Tissue Distribution; D014750:Vincristine / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005782:Gels; D010743:Phospholipids; D014750:Vincristine